How Neurotransmitters Work — The Brain's Chemical Messengers

Photo: Jeff Burkholder / Pexels
Neurotransmitters are the chemicals neurons use to talk across the gaps between them. Understanding how neurotransmitters work explains why one molecule such as serotonin can influence mood, digestion, and sleep, and why so many psychiatric and neurological drugs target these systems. An adult human brain holds an estimated 86 billion neurons, and a large share of their messages are relayed by a puff of molecules crossing a gap only 20 to 40 nanometers wide. This article follows one signal from electrical spike to chemical release to receptor response, then tours the major transmitters and what they do.
What is a neurotransmitter?
A neurotransmitter is a chemical that one neuron releases to change the behavior of another cell, which can be a neuron, a muscle fiber, or a gland. Neuroscientists use four working criteria to decide whether a molecule qualifies:
- The chemical is made in the neuron, or the neuron holds its precursor.
- It is released when the neuron is activated, and it produces a response in target cells.
- Applying it directly to the target cells reproduces that response.
- A mechanism removes it from the synapse after it has signaled.
No one knows the exact number of neurotransmitters in humans, but more than 100 have been identified. They sort loosely into amino acids (glutamate, GABA), monoamines (dopamine, serotonin, norepinephrine), peptides (endorphins), and a smaller set of oddities such as purines and gases. A handful of them carry most of the traffic.
The number of neurons is itself an estimate. A 2009 study by Frederico Azevedo, Suzana Herculano-Houzel, and colleagues in the Journal of Comparative Neurology counted cells in adult male brains with a method called the isotropic fractionator, which dissolves the tissue and counts nuclei, and reported an average of about 86 billion neurons (plus or minus roughly 8 billion) and a similar number of non-neuronal cells. That replaced the round figure of 100 billion that had circulated for decades without a direct count behind it.
How a frog heart settled an argument
For the first half of the twentieth century, scientists argued over whether nerves talk to their targets with electricity or with chemistry. The anatomy suggested a problem. Santiago Ramón y Cajal's microscope work showed that neurons are separate cells divided by a gap, a story told in more detail in our piece on Cajal and the discovery of neurons. With a gap between cells, a purely electrical hand-off looked hard to explain.
Otto Loewi settled the question with two beating frog hearts bathed in saline. Stimulating the vagus nerve slowed the first heart. When he transferred fluid from that heart to the second, the second slowed too, so a soluble substance released by the nerve had done the work. He called it Vagusstoff, "vagus substance," and it was later identified as acetylcholine. By Loewi's own account, the idea came in a dream on Easter Saturday 1921; he forgot it by morning, dreamed it again, and ran the experiment that night. The full story is in our article on the Loewi frog heart experiment.
The table lists the milestones that built the modern picture. Each entry names the people involved, so you can follow the primary literature.
| Year | Milestone | What it showed |
|---|---|---|
| 1921 | Loewi's frog heart experiment | Nerves can signal with a released chemical (acetylcholine) |
| 1936 | Nobel Prize to Loewi and Henry Dale | Recognition of chemical transmission |
| 1952 | Paul Fatt and Bernard Katz | Spontaneous tiny voltage blips at the neuromuscular junction, later understood as quantal release |
| 1973 | Timothy Bliss and Terje Lømo | Long-lasting strengthening of synapses in rabbit hippocampus |
| 1997 | Schultz, Dayan, and Montague | Dopamine neurons signal reward prediction errors |
| 2000 | Nobel Prize to Carlsson, Greengard, and Kandel | Signal transduction in the nervous system, including dopamine's role |
| 2013 | Nobel Prize to Rothman, Schekman, and Südhof | The machinery that controls vesicle traffic and release |
| 2022 | Moncrieff and colleagues | Umbrella review of the serotonin theory of depression |
How a signal crosses a synapse
A synapse is the junction where one neuron communicates with another. Chemical synapses, the kind this article is about, leave a gap of roughly 20 to 40 nanometers. Electrical synapses, built from channels called gap junctions, bring the membranes within roughly 3.5 nanometers and pass current directly. Most of the brain's signaling that matters for mood, movement, and memory runs through the chemical kind.
Think of a chemical synapse as a vending machine. The coin is calcium. The product is a packet of neurotransmitter. Nothing drops until the coin goes in, and once it does, the delivery is fast. In the fastest synapses, the chain of events before the receiving cell responds can take only a few hundred microseconds.
Step 1: The action potential arrives. An electrical spike runs down the sending (presynaptic) neuron's axon to the terminal. How that spike works is covered in our explainer on the Hodgkin-Huxley squid axon experiment.
Step 2: Calcium floods in. The spike opens voltage-gated calcium channels, and calcium ions rush into the terminal.
Step 3: Vesicles fuse and release. Calcium binds the protein synaptotagmin, which allows synaptic vesicles (membrane bubbles packed with transmitter) to fuse with the cell membrane. A family of proteins called SNAREs drive the docking and fusion. The vesicle empties into the synaptic cleft.
Step 4: The transmitter binds receptors. Molecules diffuse across the cleft and bind receptor proteins on the receiving (postsynaptic) neuron.
Step 5: The receptor responds. Depending on the receptor, binding either opens an ion channel directly or sets off a chemical cascade inside the cell. The result either pushes the receiving neuron toward firing (excitatory) or away from it (inhibitory).
Step 6: The signal is terminated. Reuptake transporters pull transmitter back into the sending neuron or nearby cells. Enzymes break it down. Or it simply diffuses away.
Quantal release: why signals come in packets
In 1952, Paul Fatt and Bernard Katz recorded spontaneous, tiny voltage blips at the neuromuscular junction, which they called miniature end-plate potentials. The blips came in sizes that were multiples of a smallest unit, which suggested that transmitter is released in discrete packets, or quanta. The modern interpretation is that one quantum corresponds to the contents of one synaptic vesicle. Release is lumpy rather than smooth, closer to a bucket brigade than a faucet.
The molecular machinery behind that lumpiness earned the 2013 Nobel Prize in Physiology or Medicine for James Rothman, Randy Schekman, and Thomas Südhof, for their discoveries of the machinery regulating vesicle traffic. Rothman identified protein complexes that let vesicles fuse with target membranes, Schekman showed in yeast that genes control vesicle transport, and Südhof found the calcium-sensitive proteins that trigger release.
Ionotropic and metabotropic receptors
A receptor decides what a neurotransmitter does, so the same molecule can excite one cell and inhibit another. Receptors fall into two broad families.
| Feature | Ionotropic receptors | Metabotropic receptors |
|---|---|---|
| Structure | The receptor is itself an ion channel | A G protein-coupled receptor that triggers an internal signaling cascade |
| Speed | Fast | Slower and longer-lasting |
| Examples | Muscle-type nicotinic acetylcholine receptors, GABA-A, NMDA, AMPA | Muscarinic acetylcholine receptors (five subtypes), GABA-B, most serotonin receptors |
| Typical job | Moment-to-moment signaling | Tuning how a circuit behaves over time |
A light switch and a dimmer is a fair comparison. Ionotropic receptors work like the switch: on or off within moments. Metabotropic receptors work like the dimmer, shifting how bright the whole room is for a while.
Serotonin shows how much the receptor matters. There are 14 known serotonin receptors, and all but one (5-HT3) are G protein-coupled. The exception, 5-HT3, is an ion channel, and its activation in a brainstem area called the chemoreceptor trigger zone can stimulate vomiting, which is why drugs that block 5-HT3 are a standard anti-nausea treatment. One transmitter, one receptor out of 14, and a very specific effect.
The major neurotransmitters
Glutamate: the main excitatory signal
Glutamate is the primary excitatory neurotransmitter in the brain. By one estimate compiled on Wikipedia, it is excitatory at well over 90 percent of the synapses in the human brain. It acts on ionotropic receptors (AMPA, NMDA, and kainate types) and on metabotropic ones.
Glutamate matters most for learning. The NMDA receptor works as a coincidence detector: it opens fully only when glutamate is bound and the receiving cell is already depolarized, so it fires when two neurons are active together. Calcium entering through it triggers changes that strengthen the synapse, including adding more AMPA receptors to the receiving membrane. This strengthening is called long-term potentiation (LTP). Terje Lømo first saw it in 1966, and Bliss and Lømo published the first full characterization in the rabbit hippocampus in 1973. LTP can last from minutes to many months, and it is the leading cellular model of how memories are stored. For the larger picture, see our articles on how memory works and Eric Kandel's sea slug memory research.
Too much glutamate is harmful. In excitotoxicity, overactivation of glutamate receptors, as can happen during stroke or traumatic brain injury, lets calcium flood neurons until they die.
Glutamate is also the raw material for GABA. In GABA-releasing neurons, the enzyme glutamate decarboxylase converts glutamate to GABA, so the brain's main accelerator and its main brake are chemical siblings.
Ketamine, used as an anesthetic, blocks NMDA receptors. A nasal-spray form of its S-enantiomer, esketamine, was approved by the U.S. Food and Drug Administration in March 2019 for treatment-resistant depression in adults, in combination with an oral antidepressant. Whether and how well that helps any one person is a question for a clinician.
GABA: the main inhibitory signal
GABA (gamma-aminobutyric acid) is the main inhibitory neurotransmitter and acts as the brake system of the nervous system. Without enough GABA activity, neurons fire too easily, and failures of inhibition are central to epilepsy.
GABA acts on two receptor families:
- GABA-A receptors are ligand-gated chloride channels. GABA binding opens a chloride pore, which pushes the cell's membrane potential toward about -75 millivolts and makes firing less likely. Benzodiazepines and barbiturates act as allosteric modulators here, meaning they bind a different site and change how the channel responds to GABA.
- GABA-B receptors are G protein-coupled and slower. Baclofen, a muscle relaxant, mimics GABA at these receptors.
The National Institute of Mental Health notes that taking benzodiazepines over long periods may lead to tolerance or even dependence, and that clinicians usually prescribe them for short periods and taper slowly. Alcohol also acts on this system, which is why its effects overlap with sedatives. See our article on how alcohol affects the body and brain.
Dopamine: prediction and motivation, not just pleasure
Dopamine is the most over-simplified molecule in popular science. The common line is that it is the pleasure chemical. The research suggests something narrower and stranger: dopamine neurons signal what is worth pursuing and whether the world is better or worse than expected.
In 1997, Wolfram Schultz, Peter Dayan, and Read Montague argued in Science that dopamine neurons in primates act as a teaching signal. Their firing tracks errors in the prediction of rewarding events. An unexpected reward causes a brief burst, an expected reward causes little change, and an expected reward that fails to arrive pushes activity below baseline. This is called a reward prediction error, and it closely resembles the error signals used in reinforcement learning, the training method behind many game-playing AI systems.
Dopamine is made from the amino acid tyrosine. Tyrosine hydroxylase converts it to L-DOPA, and a second enzyme converts L-DOPA to dopamine. The human brain has only about 400,000 dopamine neurons by one estimate, a tiny group compared with 86 billion neurons, but their axons reach into many regions.
The major pathways each do something different:
- Mesolimbic and mesocortical pathways run from the ventral tegmental area to the nucleus accumbens and prefrontal cortex, supporting motivation, reward, and cognition.
- Nigrostriatal pathway runs from the substantia nigra to the striatum and supports movement. This is the pathway that degenerates in Parkinson's disease.
- Tuberoinfundibular pathway reaches the pituitary gland, where dopamine inhibits the release of prolactin.
Dopamine cannot cross the blood-brain barrier, so it has to be made inside the brain. That is why Parkinson's disease is treated with levodopa, the precursor, which does cross. Think of it as sending flour instead of bread through a security checkpoint, because the bakery is on the other side. The Nobel Prize in 2000 went partly to Arvid Carlsson, whose work established dopamine as a neurotransmitter in its own right and helped lead to levodopa therapy.
Addictive drugs work on this system by increasing dopamine release or by blocking its reuptake. Cocaine blocks reuptake, while amphetamines promote release. For a deeper treatment, see the dopamine system explained and how dopamine really works, and for the broader disease picture, the psychology of addiction.
Serotonin: mood, sleep, and the gut
Serotonin (5-hydroxytryptamine, or 5-HT) is made from the amino acid tryptophan. About 90 percent of the body's serotonin is produced in the gastrointestinal tract by enterochromaffin cells, where it helps regulate intestinal movement. The serotonin in the brain comes mainly from neurons of the raphe nuclei, a column of nine clusters along the brainstem midline. Those neurons project widely across the brain. The gut side is covered in our explainer on the gut microbiome.
In the brain, serotonin systems are linked to mood, sleep, appetite, and social behavior. Serotonin is also a precursor to melatonin in the pineal gland, which ties it to the sleep cycle.
Drugs that act on serotonin include:
- SSRIs (selective serotonin reuptake inhibitors) block the serotonin transporter, so serotonin stays in the synapse longer. They are commonly prescribed for depressive and anxiety disorders. The NIMH notes that antidepressants usually take 4 to 8 weeks to work, and that combining them with certain other substances can cause serotonin syndrome, which is rare but can be life-threatening.
- MAO inhibitors block monoamine oxidase, the enzyme that breaks serotonin down.
- Appetite drugs have targeted the 5-HT2C receptor. One of them, lorcaserin (Belviq), was withdrawn from the U.S. market in 2020 after the FDA concluded that its risks outweighed its benefits. In the CAMELLIA-TIMI 61 trial, 7.7 percent of patients on lorcaserin were diagnosed with cancer compared with 7.1 percent on placebo.
The lorcaserin story is a useful reminder that tinkering with a widely distributed transmitter system has consequences that are hard to predict from the mechanism alone.
For the neuroscience of mood disorders, see our article on the neuroscience of depression.
Acetylcholine: muscles, attention, and memory
Acetylcholine (ACh) is the transmitter Loewi found. It works in two very different places.
At the neuromuscular junction, motor neurons release ACh onto skeletal muscle. It binds nicotinic receptors, which are ion channels. Sodium flows into the muscle cell and the muscle contracts. The enzyme acetylcholinesterase breaks ACh down within moments, which keeps muscles from locking on. Poisons make the logic visible: nerve agents such as sarin and VX inhibit acetylcholinesterase, so ACh piles up and can paralyze the muscles needed for breathing. Botulinum toxin suppresses ACh release, which also causes paralysis. Curare blocks the muscle-type nicotinic receptor.
In the brain, cholinergic neurons in the basal forebrain project to the cortex and hippocampus and support attention and memory. Many ACh effects in the brain run through muscarinic receptors, a family of five G protein-coupled subtypes (M1 to M5). Damage to the basal forebrain cholinergic system is associated with the memory deficits of Alzheimer's disease, and drugs that inhibit acetylcholinesterase, such as rivastigmine and donepezil, are used to raise acetylcholine's activity in that setting. For more, see the biology of Alzheimer's disease.
Norepinephrine: alertness and stress
Norepinephrine (noradrenaline) is built from dopamine by the enzyme dopamine beta-hydroxylase. The brain's main source is the locus coeruleus, a small brainstem nucleus with an estimated 15,000 neurons in primates, which nonetheless projects widely across the brain and spinal cord. Norepinephrine raises arousal and vigilance, and stress strongly activates this system alongside the hypothalamic-pituitary-adrenal axis.
Norepinephrine is also a hormone. When the sympathetic nervous system activates the adrenal medulla, it releases norepinephrine and epinephrine into the bloodstream. The same molecule is a neurotransmitter in the brain and a hormone in the blood, which makes the old line between the two fuzzier than textbooks suggest. For the hormonal side, see our article on cortisol and the stress response.
Drugs that act here include SNRIs (serotonin-norepinephrine reuptake inhibitors), which block reuptake of both transmitters, and atomoxetine, one of several norepinephrine-acting drugs used for ADHD. Beta-blockers block beta-adrenergic receptors and are used for some heart and blood-pressure conditions. Our article on the neuroscience of ADHD covers the attention side.
Endorphins and other peptides
Endorphins are neuropeptides, which are larger than classic transmitters and act more slowly. They bind opioid receptors to reduce pain. Morphine and heroin mimic them at the same receptors, which explains both their power as painkillers and their risk for dependence. Peptides are often released alongside a classic transmitter from the same neuron, so a single cell can send a fast message and a slower, modulating one at once.
The major neurotransmitters at a glance
| Neurotransmitter | Class | Typical role | Receptor types | Example drug or disorder link |
|---|---|---|---|---|
| Glutamate | Amino acid | Main excitatory signal; learning | AMPA, NMDA, kainate, metabotropic | Ketamine blocks NMDA; stroke excitotoxicity |
| GABA | Amino acid | Main inhibitory signal | GABA-A (channel), GABA-B (G protein) | Benzodiazepines modulate GABA-A; baclofen acts on GABA-B |
| Dopamine | Monoamine | Reward prediction, motivation, movement | G protein-coupled | Levodopa in Parkinson's; cocaine blocks reuptake |
| Serotonin | Monoamine | Mood, sleep, gut movement | 14 types; 13 G protein-coupled, one channel (5-HT3) | SSRIs block reuptake; 5-HT3 blockers prevent nausea |
| Acetylcholine | Ester | Muscle contraction, attention, memory | Nicotinic (channel), muscarinic M1 to M5 | Sarin inhibits breakdown; cholinesterase inhibitors in Alzheimer's |
| Norepinephrine | Monoamine | Arousal, stress response | G protein-coupled | SNRIs; atomoxetine; beta-blockers |
| Endorphins | Peptide | Pain relief | Opioid receptors | Morphine mimics them |
How drugs and toxins hijack the system
Because every neurotransmitter has a life cycle of synthesis, release, receptor binding, and removal, each step offers a place to interfere. Many familiar drugs and poisons are best understood as a wrench thrown into one stage.
| Where it interferes | Mechanism | Example |
|---|---|---|
| Supply the raw material | Provide a precursor that crosses the blood-brain barrier | Levodopa for dopamine |
| Trigger or block release | Force release, or stop it | Amphetamine promotes dopamine release; botulinum toxin blocks acetylcholine release |
| Imitate the transmitter | Bind the receptor and activate it | Morphine at opioid receptors |
| Block the receptor | Occupy the receptor without activating it | Curare at muscle nicotinic receptors |
| Block reuptake | Keep the transmitter in the cleft longer | SSRIs, SNRIs, cocaine |
| Block breakdown | Inhibit the degrading enzyme | MAO inhibitors; sarin and cholinesterase inhibitors |
| Modulate the channel | Change how a receptor responds to the natural transmitter | Benzodiazepines at GABA-A |
Seen this way, the logic of the pharmacology is less mysterious. A drug that blocks a transporter will raise transmitter levels in the cleft only where that transmitter is being released, which is why effects depend on the circuit and not only on the molecule.
Why "chemical imbalance" is too simple
The phrase "chemical imbalance" has long been used to explain depression, most often as low serotonin. The evidence for that specific claim has been challenged. In 2022, Joanna Moncrieff and colleagues published a systematic umbrella review of the serotonin theory of depression in Molecular Psychiatry. As reported in coverage of the paper, they found no association between depression and the serotonin metabolite 5-HIAA in two meta-analyses, none with plasma serotonin in cohort studies, and lower serotonin concentrations in people taking antidepressants. The authors concluded that decades of research have not produced consistent evidence that depression is caused by abnormal serotonin levels or activity.
Two cautions belong beside that finding. First, the review tested a particular causal theory and did not test whether antidepressants help people, which is a separate question that depends on the individual and belongs with a clinician. The authors themselves cautioned against stopping antidepressants without medical advice, because of the risk of withdrawal effects. Second, the weakness of one simple theory does not make neurotransmitters irrelevant. It means that the systems are tangled: a drug that changes serotonin signaling can alter mood through downstream changes in circuits, not by topping up a missing quantity.
The same lesson applies elsewhere. Dopamine excess in mesolimbic circuits is a long-standing hypothesis for the positive symptoms of schizophrenia, and antipsychotic drugs block dopamine D2 receptors. Reduced dopamine and norepinephrine signaling in prefrontal circuits is a common model for ADHD. These are models that organize evidence, and they come with exceptions. Correlation between a transmitter and a symptom does not establish that the transmitter caused it, because brain circuits adapt, and treatments change many things at once.
When neurotransmitter systems go wrong
The following conditions are often described in terms of neurotransmitters. Each description is simplified, and the linked articles go deeper.
- Parkinson's disease. Loss of dopamine-producing neurons in the substantia nigra causes the movement symptoms. Levodopa supplies the precursor.
- Alzheimer's disease. Early loss of basal forebrain cholinergic neurons fits the early attention and memory problems, though the disease involves much more than acetylcholine.
- Depression. Serotonin, norepinephrine, dopamine, and glutamate circuits are all implicated, with no single deficit established.
- Anxiety disorders. Researchers point to overactive threat circuits involving norepinephrine and reduced inhibitory tone. Treatments include drugs that act on GABA, serotonin, and norepinephrine systems, plus psychotherapy. See anxiety neuroscience.
- Epilepsy. Seizures reflect runaway excitation, with inhibitory failure central to many forms.
- Addiction. Drugs overstimulate reward circuits, and the brain adapts with changes that underlie tolerance and dependence.
Myths worth dropping
"Dopamine is the pleasure molecule." It is closer to a want-and-learn signal. Enjoying something involves other systems too, which researchers have linked to opioid and endocannabinoid signaling.
"Serotonin is the happiness chemical." Most of the body's serotonin sits in the gut, and the brain's serotonin acts through 14 receptor types with different effects. A label that simple cannot hold.
"A natural boost is easy to get." Measuring neurotransmitter release in a living human brain is hard. Claims that a specific food or habit raises serotonin or dopamine usually rest on indirect evidence or animal studies, so treat them with caution.
"More is better." Too much of a transmitter can be as harmful as too little. Glutamate excitotoxicity and serotonin syndrome both come from overactivity.
The takeaway
Neurotransmitters are less a set of mood chemicals than a vocabulary. A small number of molecules carry a huge range of meaning because the message depends on the receptor receiving it, the circuit it reaches, the timing of its release, and the other transmitters released alongside it. That is why one drug can calm anxiety and cause drowsiness, and why a transmitter that supports learning in one region can damage cells when it is released in excess. The most honest summary of the field is that we understand the machinery of a single synapse in remarkable detail and the behavior of whole circuits far less well, and the gap between those two levels is where most open questions about mental health still sit.
FAQ
Q: What is the difference between a neurotransmitter and a hormone? A: Neurotransmitters act locally across synapses, with fast and specific effects. Hormones travel through the bloodstream to distant targets, working more slowly and broadly. The line blurs for some molecules. Norepinephrine is a neurotransmitter in the brain and a hormone when the adrenal medulla releases it into the blood.
Q: How fast is synaptic transmission? A: At the fastest chemical synapses, the process before the receiving cell responds can take only a few hundred microseconds. Metabotropic receptor effects are slower and last longer. Electrical synapses, in which membranes sit about 3.5 nanometers apart, pass current directly and are faster still.
Q: Do antidepressants work by fixing a chemical imbalance? A: The simple version of that story, that depression is caused by low serotonin, is not supported by the evidence reviewed in a 2022 umbrella review in Molecular Psychiatry. SSRIs do block the serotonin transporter, but the NIMH notes that antidepressants usually take 4 to 8 weeks to work, so the benefit seems to involve slower downstream changes. Whether an antidepressant is appropriate is a decision for a person and their clinician.
Q: Is dopamine really about pleasure? A: Mostly not. Research since the 1990s, including the 1997 Science paper by Schultz, Dayan, and Montague, shows dopamine neurons signaling errors in the prediction of reward, which supports learning and motivation. Pleasure itself involves other systems, including opioid signaling.
Q: Can you raise serotonin or dopamine naturally? A: Evidence is limited, mainly because neurotransmitter release is hard to measure in living human brains. Exercise, sleep, and diet are linked to mood in many studies, but the idea that a specific food or habit "boosts" a specific transmitter usually rests on indirect or animal evidence. Anyone concerned about mood or attention should talk with a clinician.
Q: How do recreational drugs affect neurotransmitters? A: They tend to hijack an existing step. Cocaine blocks reuptake of dopamine and other monoamines, and amphetamines promote dopamine release. Opioids such as heroin and morphine mimic endorphins at opioid receptors. Alcohol affects GABA signaling. The brain adapts to repeated surges, which underlies tolerance and dependence.
Q: How many neurotransmitters are there? A: Nobody knows the exact number, but more than 100 have been identified. A handful, including glutamate, GABA, dopamine, serotonin, acetylcholine, and norepinephrine, account for much of the brain's signaling and most drug targets.
Sources
- Wikipedia, Chemical synapse, for cleft width (20 to 40 nm), electrical synapse gap (about 3.5 nm), and synaptic delay (compiling Bear, Connors, and Paradiso; Kandel, Schwartz, and Jessell).
- Wikipedia, Neurotransmitter, for the working criteria, the count of more than 100, and the prevalence of glutamate and gut serotonin.
- Wikipedia, Otto Loewi, for the 1921 experiment and 1936 Nobel Prize.
- Wikipedia, Long-term potentiation, for the 1973 Bliss and Lømo work and AMPA receptor insertion.
- Wikipedia, Dopamine, Serotonin, Norepinephrine, Acetylcholine, GABA receptor, and Glutamic acid, for synthesis pathways, receptor families, and drug mechanisms.
- Schultz, W., Dayan, P., and Montague, P.R. (1997), A neural substrate of prediction and reward, Science 275(5306): 1593-1599.
- National Institute of Mental Health, Mental health medications.
- U.S. Food and Drug Administration (February 13, 2020), FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market.
- Azevedo, F.A.C., et al. (2009), Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain, Journal of Comparative Neurology 513(5): 532-541.
- Moncrieff, J., et al. (2022), The serotonin theory of depression: a systematic umbrella review of the evidence, Molecular Psychiatry, doi:10.1038/s41380-022-01661-0.
- Fatt, P., and Katz, B. (1952), Spontaneous subthreshold activity at motor nerve endings, Journal of Physiology 117(1): 109-128.
- The Nobel Prize in Physiology or Medicine 2000 (Carlsson, Greengard, Kandel) and 2013 (Rothman, Schekman, Südhof), nobelprize.org.
- Purves, D., et al., Neuroscience, 6th edition, Sinauer Associates, 2018.
- Bliss, T.V., and Collingridge, G.L. (1993), A synaptic model of memory: long-term potentiation in the hippocampus, Nature 361: 31-39.
Follow new articles
Add SciHub101 to your feed reader to see new science and technology stories.
About the Author
SciHub101 is an independent science and technology publication founded and edited by Buğra Sözeri, a software engineer and app developer based in Türkiye. AI tools assist with drafting and research. Source documentation in the existing archive is uneven, and articles are being reviewed and corrected. The Editorial Team byline identifies editorial responsibility; it does not certify specialist or independent human review. Where we compare products, anything built by our own team is labelled as such — see the editorial guidelines and About page for how corrections and disclosures work.
Related Articles

Oxytocin — The Bonding Hormone and What It Actually Does
What oxytocin does in the body and brain: childbirth, milk release, bonding, and trust, plus why the love hormone label and nasal sprays claim more than evidence shows.

Cortisol and the Stress Response — How Your Body Handles Pressure
How cortisol and the HPA axis work, why the daily cortisol rhythm matters, what chronic stress does to the body, and what the evidence says about cortisol.

The Dopamine System Explained: Reward, Motivation, and Why It's Not What You Think
Dopamine is called the 'pleasure chemical' — but that's not quite right. It's actually about anticipation, prediction errors, and the drive to seek. Here's the real neuroscience.

Complete Biology Guide 2026 — How Life Works
The complete guide to biology in 2026: cells and genetics, evolution, the human body, neuroscience, disease, immune systems, and the future of genetic engineering.

How the Gut Microbiome Affects Mental Health
Your gut microbiome influences your brain through the vagus nerve, immune signaling, and microbial chemistry. Here is what the mechanisms, the animal work, and the human trials actually show, and where the evidence stops.

What Happens to Your Body with No Sleep for 24 to 72 Hours
After 17 hours without sleep, your cognitive performance matches someone with a blood alcohol concentration of 0.05% — legally impaired to drive in most countries. After 24 hours, the equivalent is 0.10% — above the legal limit in all US states. After 72 hours, hallucinations are common, emotional regulation breaks down, and the immune system's ability to mount a response is measurably compromised. Sleep deprivation is not discomfort — it is a physiological insult to nearly every system in the body, and it unfolds on a precisely documented timeline.